My Approach to the use of NOACs for stroke prevention in patients with atrial fibrillation.
نویسنده
چکیده
Publisher Rights Statement: NOTICE: this is the author’s version of a work that was accepted for publication in Trends in Cardiovascular Medicine. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published inTrends in Cardiovascular Medicine [VOL 24, ISSUE 4, August 2014] DOI: 10.1016/j.tcm.2014.05.012
منابع مشابه
Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis
BACKGROUND Much direct evidence has proved that the novel oral anticoagulants (NOACs) are noninferior or superior to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation, and lead to a relevant decrease in bleeding profiles. However, no study has compared NOACs with each other head-to-head. The current study is a network meta-analysis aiming to assess the efficacy and...
متن کاملDo NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation?
Guidelines recommended oral anticoagulant (OAC) for ischemic stroke patients related to atrial fibrillation (AF). But, underprescription or underdose of warfarin was observed worldwide. We aimed to explore if the use of antithrombotic therapy in nonvalvular AF (NVAF) ischemic stroke patients improved after novel oral anticoagulants (NOACs) became available. Between January 2011 to December 2013...
متن کاملNon-Vitamin K Oral Anticoagulants in Stroke Patients: Practical Issues
Non-vitamin-K oral anticoagulants (NOACs) represent a major advance in the prevention of stroke in patients with atrial fibrillation (AF), offering a similar, if not superior, efficacy and safety profile and several practical advantages over oral vitamin K antagonists (VKAs). The rapid onset of action of the NOACs, their relatively short half-live, and the availability of specific reversal agen...
متن کاملNon-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis.
BACKGROUND AND PURPOSE The use of vitamin K antagonists (VKAs), the cornerstone treatment for stroke prevention in patients with atrial fibrillation, is limited by the perceived risk of serious bleeding in Asia. Non-VKA oral anticoagulants (NOACs) are safer alternatives. Here, we evaluate performance differences of NOACs between Asians and non-Asians. METHODS We compared efficacy and safety o...
متن کاملNon–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation
Stroke prevention with vitamin K antagonists (VKAs) is essential in the management of atrial fibrillation (AF). However, it has been generally perceived that Asian patients are naturally more sensitive to VKAs and have unacceptably higher rates of intracranial hemorrhage (ICH) even when international normalized ratio is ideally maintained. Consequently, VKAs have been largely underused or under...
متن کاملNon-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation
Atrial fibrillation (AF) is a significant problem for the aging population and remains a major factor underlying stroke risk. Warfarin anticoagulation has been proven effective for stroke prevention in AF, but can be difficult to manage and requires frequent monitoring. The non-vitamin K antagonist oral anticoagulants (NOACs) have been shown to be as effective as warfarin for stroke prevention ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Trends in cardiovascular medicine
دوره 24 6 شماره
صفحات -
تاریخ انتشار 2014